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Abstract: An elevated intraocular pressure (IOP) is one of the most important risk factors 
for the development of glaucoma, which causes progressive optic neuropathy. Lowering IOP 
is currently the only therapeutic approach to the treatment of glaucoma. Tafluprost, a novel 
prostaglandin analogue, was recently launched onto the market as an ocular hypotensive agent. 
Tafluprost is potent in its affinity for the prostanoid FP receptor and in its intraocular lower-
ing efficacy. Moreover, it enhances the ocular hemodynamics and has neuroprotective effects. 
Clinical studies have demonstrated its efficacy at decreasing intraocular pressure in patients 
with open-angle glaucoma or ocular hypertension.
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pressure
Introduction
To date, four prostaglandin (PG) derivatives (unoprostone, latanoprost, travoprost and 
bimatoprost) have been marketed across the world. In addition, in 2008 tafluprost was 
marketed in some European countries and in Japan. Prost-type PG derivatives (that 
is, PG derivatives other than unoprostone) are now the drugs of first choice for the 
treatment of glaucoma because of their potent intraocular pressure (IOP)-lowering 
activity, the low likelihood of systemic adverse reactions, the once-daily application, 
and good patient adherence. As of end July 2009, tafluprost has been approved in 21 
countries. No preservative-free tafluprost preparation has yet been marketed in Japan, 
even though both a preservative-containing preparation (Tapros®) and a preservative-
free preparation (Taflotan®) have been marketed in other countries. This review will 
describe the pharmacological profile of tafluprost (the latest PG derivative) and also 
the clinical studies of this drug conducted across the world, while focusing especially 
on those conducted in Japan.
Pharmacological profile of tafluprost
Tafluprost was developed by Santen Pharmaceutical Co. Ltd. (Osaka, Japan) and Asahi 
Glass Co. Ltd. (Tokyo, Japan), their original concept having been to develop a new 
product with an efficacy and safety comparable to or higher than those of latanoprost 
(a prostanoid FP receptor agonist).
Prost-type PG derivatives (ie, those other than unoprostone), were discovered as 
compounds that retained the 15-position hydroxyl group of natural PGF2α, and had 
high pharmacological activity. The hydroxyl group at the 15-position was considered Clinical Ophthalmology 2010:4 164
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indispensable for the manifestation of the activity of PGs.1 
However, tafluprost is a novel PGF2α derivative in which 
the 15-position hydroxyl group is substituted by 2 fluorine 
atoms (Figure 1). Because of this substitution, ketonization 
by 15-hydroxy-dehydrogenase (one of the major pathways 
involved in the metabolization of PGs) does not occur with 
this compound. As a result, it is metabolized only through 
beta-oxidation of the alpha-chain of PG skeleton.2 Because 
of this lack of one pathway for its metabolization, tafluprost 
may expected to have a prolonged action, but it has been 
shown to lack a tendency to accumulate.2 In PG derivatives 
other than bimatoprost, the alpha-chain ending of the PG 
skeleton has been isopropyl-esterified, and for this reason 
these derivatives are converted into an active form (carboxylic 
acid form) by corneal esterase, and penetrate rapidly into the 
anterior chamber of the eye. Tafluprost, too, is an isopropyl-
ester type of PG derivative.
It has been reported that tafluprost not only has an affinity 
for the FP receptor that is about 12 times higher than that 
of latanoprost, but that it has almost no potential to bind to 
the other receptors.3 Among the other PG derivatives, the 
affinity of travoprost for the prostanoid FP receptor has been 
reported to be 2.8 times as high as that of latanoprost.4 For 
both unoprostone and bimatoprost, the receptors on which 
they act were uncertain at the time of launch onto the market. 
However, each had been reported to have a low affinity for 
the prostanoid FP receptor.5,6 Later, only nonmetabolized 
bimatoprost was found not to bind to the conventional FP 
receptor, but instead to the prostamide receptor, which is 
a complex receptor consisting of FP and splice-variant FP 
receptors.7 Figure 2 shows images indicating the receptor-
binding affinities of PG derivatives for various prostanoid 
receptors. A simple summary of these reports on the affinities 
of the existing PG derivatives for the FP receptor would be 
that tafluprost has the highest affinity for the FP receptor 
among the PG derivatives currently available (notably, higher 
than that of latanoprost). We previously reported that the 
IOP-lowering activity of each of these PG derivatives was 
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Figure 1 Structure of tafluprost.
Figure 2 Receptor affinities of various prostaglandin derivatives (schematic representation).
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absent in prostanoid FP receptor-knockout mice, indicating 
that the FP receptor is involved to a greater or lesser extent 
in the IOP-lowering action of each PG derivative.8,9
Efficacy and safety of tafluprost –  
nonclinical trials
The IOP-lowering activity of tafluprost has been dem-
onstrated both in ocular normotensive monkeys and in 
laser-induced ocular hypertensive monkeys.3 In the former 
the maximal IOP reductions achieved with a single dose of 
tafluprost (0.00002 to 0.0025%) were dose-dependent, with 
statistical significance being reached at doses of 0.0005 and 
0⋅0025%, and the potency of tafluprost at 0⋅0005% was 
almost equal to that of latanoprost at 0⋅005% (Figure 3).3 
Similarly, in laser-induced ocular hypertensive monkeys, 
single-dose applications of tafluprost (0.00002 to 0.0025%) 
induced a dose-dependent IOP reduction.3 When normo-
tensive monkeys received repeated doses of tafluprost 
(0.0015%, 0.0025%, or 0.005%) once daily for 5 days, this 
drug exhibited IOP-lowering effects not only on the first day, 
but also on the third and fifth days of administration, with-
out an attenuation of efficacy over time (Figure 4).3 When 
0.005% of latanoprost was administered instead in the same 
study, the IOP measured at 24 hours after each dose was 
equal to the baseline IOP level. However, when any one of 
the above concentrations of tafluprost was administered, the 
IOP levels at the trough-points on the third to fifth days were 
significantly lower than those in the vehicle-treatment group 
(Figure 4).3 These results suggest that the duration of action 
of tafluprost may become longer upon repeated dosing.
Like latanoprost, tafluprost lowers IOP by stimulat-
ing the outflow of aqueous humor through the uveoscleral 
passway.3 Although latanoprost and tafluprost lower IOP 
through actions on the same receptor and through the same 
mechanism, the magnitude of the IOP reduction in a given 
individual may differ between these two drugs. In our recent 
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Figure 3 Intraocular pressure (IOP)-lowering effects of a single application of taflu-
prost in normotensive monkeys.
reproduced with permission from  Takagi  Y, Nakajima  T, Shimazaki A, et al. Pharmacologi-
cal characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an 
ocular hypotensive drug. Exp Eye Res. 2004;78:768–776.3 Copyright © 2004 elsevier.
Notes: Tafluprost is indicated as AFP-168.
Data represent the mean ± SeM for 12 animals. **P  0.01 vs vehicle (Tukey–Kramer 
test).
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Figure 4 Intraocular pressure (IOP)-lowering effects of once-daily multiple applications of tafluprost and latanoprost in normotensive monkeys.
reproduced with permission from Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an 
ocular hypotensive drug. Exp Eye Res. 2004;78:768–776.3 Copyright © 2004 elsevier.
Notes: Tafluprost is indicated as AFP-168.
iOP change was calculated from time 0 on day 1. Drugs were instilled at 10:30 a.m. on each day from day 1 to day 5. Data represent the mean + SeM. for 10 animals. *P  0.05; 
**P  0.01 vs vehicle (Dunnett’s multiple-range test).Clinical Ophthalmology 2010:4 166
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study on monkeys that had a low susceptibility to latanoprost 
and displayed an inadequate reduction of IOP in response to 
latanoprost, the magnitude of the IOP reduction induced by 
tafluprost (0.0015%) was greater than that induced by latano-
prost (0.005%) in all ten monkeys tested.10 This suggests that 
switching to tafluprost may be useful in cases in which the 
IOP reduction achieved with latanoprost is insufficient.
One of the known adverse reactions to PG derivatives is 
pigmentation of the iris and/or eyelids. Interesting data have 
been collected relating to the likelihood of tafluprost inducing 
such pigmentation. Melanoma cells that had been incubated 
for 4 days in a medium supplemented with a high concen-
tration of tafluprost failed to exhibit the elevated melanin 
content seen in cultures containing the same concentration of 
latanoprost (Figure 5).3 Admittedly, a very high concentration 
of each drug was used in this study. Nevertheless, the lack 
of reaction in the tafluprost-treated cells, despite the pres-
ence of such a reaction in the latanoprost-treated ones, may 
indicate (a) that the incidence of iris or eyelid pigmentation 
will be low with tafluprost and (b) that if such pigmentation 
does develop following treatment with this drug, it will not 
be severe.
Other data have raised the possibility that tafluprost might 
improve blood flow as well as other PG derivatives. For 
instance, Izumi N et al11 noted that administration of taflu-
prost ophthalmic solution elevated feline retinal blood flow. 
Moreover, in a rabbit model of disturbed blood flow induced 
by administration of endothelin-1 (ET-1) into the vitreous, an 
improvement in blood flow was demonstrated with tafluprost.12 
Indeed, when latanoprost, travoprost, or tafluprost ophthalmic 
solution was administered 2 hours before the intravitreous 
injection of ET-1, the disturbance of the retinal blood flow 
was significantly inhibited in all the groups. However, such a 
significant effect was observed only in the tafluprost-treated 
group when the same ophthalmic solutions were administered 
4 hours before intravitreous injection of ET-1. This result 
suggests that the ocular blood flow-improving effect may 
be more prolonged with tafluprost than with latanoprost or 
travoprost. Regarding the mechanism responsible for the 
blood flow improvement, Dong Y et al13 noted that taflu-
prost relaxed rabbit ciliary artery smooth muscle, and that 
the relaxation was not dependent on endothelium-derived 
factors. Moreover, it apparently did not involve a reduction 
in agonist-induced Ca2+ influx or increased Ca2+ extrusion into 
the extracellular space. However, they did obtain evidence 
that the tafluprost-induced relaxation might be due, at least 
in part, to an inhibition of the capacitative entry of extracel-
lular Ca2+. Since we really do not have sufficient means of 
measuring blood flow in animal models and human eyes, 
the clinical relevance of improvement of ocular blood flow 
by PG derivatives including tafluprost should be verified in 
the future study.
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Figure 5 Effects of tafluprost on melanin formation in B16 melanoma cells.
reproduced with permission from Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an 
ocular hypotensive drug. Exp Eye Res. 2004;78:768–776.3 Copyright © 2004 elsevier.
Notes: The carbonic acid form of tafluprost is indicated as AFP-172, and that of latanoprost as PhXA85.
Drugs were added to the culture medium for 4 days. Data represent the mean ± SeM from four experiments. *P  0.05, vs vehicle (Dunnett’s multiple-range test).Clinical Ophthalmology 2010:4 167
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In a recent study, Kanamori et al14 reported neuropro-
tective effects of tafluprost. In a rat model in which retinal 
ganglion cell apoptosis was induced by serum-removal or by 
glutamate exposure, tafluprost suppressed the apoptosis in 
a concentration-dependent manner. They also noted that in 
a rat model of optic-nerve crush, treatment with tafluprost 
ophthalmic solution increased the survival rate of retinal 
ganglion cells.
Efficacy and safety of tafluprost –  
clinical trials
Efficacy – IOP-lowering effect
Clinical studies on tafluprost have been carried out both in Western 
countries14–19 and in Japan, in each case using preservative-
containing tafluprost preparations. Two phase I studies were 
conducted in England, one on healthy Japanese men and one on 
healthy non-Japanese men.15,16 The therapeutic concentration of 
tafluprost has been set at 0.0015% on the basis of results from 
phase II dose-response study performed in Japan. In Japan, 
three phase III clinical studies have been carried out using 
taflprost at that concentration (0.0015%). Incidentally, for the 
dosage and administration of this drug, it is indicated that it 
should be administered once daily (one drop/dose).
Of the three phase III clinical studies conducted in 
Japan, one was designed as a non-inferiority study aimed at 
comparing the efficacy of tafluprost with that of latanoprost. 
In that study – a randomized, single-blind comparative study 
involving 109 patients with primary open angle glaucoma 
or ocular hypertension (reference drug: latanoprost oph-
thalmic solution) – the magnitude of the IOP reduction in 
the tafluprost and latanoprost treatment group after 4 week 
administration was 6.6 ± 2.5 mmHg (27.6 ± 9.6%) and 6.2 ± 
2.5 mmHg (25.9 ± 9.7%), respectively. Thus endorsing the 
noninferiority of this drug versus latanoprost (Figure 6).20 
Moreover, the percentage of patients showing a reduction of 
20% or more in IOP was 80.4% in the tafluprost treatment-
group against 70.6% in the latanoprost-treatment group.
The second phase III clinical study of tafluprost 
was designed as a long-term dosing study primarily 
aimed at evaluating its safety in prolonged use. In that 
study – involving 351 patients with open angle glaucoma 
(including normotensive glaucoma) or ocular hypertension – 
the magnitude of the IOP reduction seen following treatment 
with tafluprost studied within the range 4.9 to 5.7 mmHg 
throughout the 52-week study period. Thus, this drug exerted 
its IOP-lowering effect in a stable manner during prolonged 
use (see Product Overview: http://www.santen.co.jp/medical/
common/pdf/info_package/tenpu/tapros.pdf).
The third phase III clinical study was designed as a com-
parative study aimed at evaluating the efficacy of tafluprost 
in patients with normal tension glaucoma. According to the 
results of the epidemiological survey of glaucoma in Japan 
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carried out in Tajimi City, Gifu Prefecture in 2000 and 2001 
(often referred to as the “Tajimi Study”), the prevalence of 
glaucoma at ages over 40 is 5% in Japan, and normal ten-
sion glaucoma accounts for more than 70% of all glaucoma 
cases.21 To date, however, no IOP-lowering agent has been 
shown in clinical trials to be effective against normal tension 
glaucoma (the most frequent type of glaucoma in Japan). In 
unpublished randomized masked comparative study involv-
ing 94 patients with normotensive glaucoma (reference drug: 
placebo ophthalmic solution), the magnitude of the IOP 
reduction in the tafluprost-treatment group was 4.0 mmHg 
(95% confidence interval: 3.5 to 4.5 mmHg), and this was 
significantly greater than that in the placebo-treatment group 
(Figure 7).
The following clinical studies were conducted not in 
Japan, but in Europe. For tafluprost versus latanoprost, 
noninferiority was demonstrated by ANOVA (and almost 
by ANCOVA) in a phase III, 24-month study in patients 
with open-angle glaucoma or ocular hypertension.17 
In addition, the IOP-lowering efficacy of tafluprost in 
adjunctive use with timolol demonstrated by Egorov and 
Ropo.18 A clinical equivalence between preservative-
free and preservative-containing prescriptions has been 
reported both by Uusitalo H et al19 in healthy volunteers, 
and by Hamacher T et al22 in patients with glaucoma or 
ocular hypertension. Thus the penetration of tafluprost 
into the anterior chamber is apparently not affected by 
preservative benzalkonium chloride. At present, there are 
insufficient clinical data comparing tafluprost and other 
PG derivatives because of its short marketing history. 
Further comparison studies should be conducted to verify 
the potential efficacy of tafluprost.
Safety
The phase III clinical trial of 4 weeks aimed at comparing to 
latanoprost revealed that the incidence of adverse reactions 
did not differ between those two treatment groups (40.0% 
and 48.1%, respectively, P = 0.443, Fisher’s exact test). The 
most common adverse reaction was conjunctival hyperemia 
(16.4%, n = 55), which was higher than that of latanoprost 
(13.0%, n = 54), but not significant. Of the total population 
studied in Japan (483 patients), 326 patients (67.5%) showed 
adverse reactions to tafluprost ophthalmic solution 0.0015% 
(including abnormal changes in laboratory parameters). 
The most common adverse reactions reported were conjunc-
tival hyperemia (151 cases, 31.3%), eyelash abnormalities 
(93 cases, 19.3%), itching sensation (85 cases, 17.6%), 
ocular irritation (65 cases, 13.5%), and iris pigmentation (39 
cases, 8.1%). No adverse reaction unknown for existing PG 
derivatives was noted. The adverse reactions were mild in 
more than 95% of all cases, and no severe adverse reaction 
was noted. Like the other PG derivatives, this drug requires 
particular care when used for aphakic eyes or intraocular lens-
implanted eyes, in patients with bronchial asthma or a history 
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of it, in patients with endophthalmitis (iritis, uveitis), or in 
pregnant, women, or lactating women, and so on. Patients 
with herpes infection are not included in the group requiring 
particularly careful administration. These adverse reactions 
by tafluprost were comparable to other new PG derivatives 
such as travoprost and bimatoprost.
Tafluprost 0.0015% ophthalmic solution 
for the Japanese market
Table 1 shows the composition of the product to be marketed 
in Japan. It contains 15 µg tafluprost per mL, a concentration 
that is the lowest among the PG derivative preparations on the 
Japanese market. It is a clear, colorless aqueous ophthalmic 
solution, with a pH of 5.7 to 6.3 and an osmotic pressure 
ratio of 1.0 to 1.1.
This product is intended to be stored at room temperature, 
and its expiration period is 3 years after manufacture. It is 
provided in a plastic bottle called “Dimple®” bottle. Hyodo 
et al24 reported that this container was highly praised in an 
evaluation of various indicators of the impressions of users, 
and that elderly patients (65 years old) could use it as easily 
as nonelderly patients. Thus, since this ophthalmic solution 
can be stored at room temperature and is supplied in a highly 
comfortable container, there is expected to be high adherence 
of patients to the dosing instructions.
Conclusion
Tafluprost 0.0015% ophthalmic solution contains a new PG 
analogue with an IOP-lowering activity and safety compa-
rable to those of latanoprost. Since it can be stored at room 
temperature and is supplied in a container that patients find 
easy to handle, there is expected to be a high patient adher-
ence to the dosing instructions. Tafluprost is thus a promising 
new alternative for glaucoma treatment.
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